Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT03358875 · COMPLETED
Trial details
- NCT number
- NCT03358875
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-30
- Primary completion
- 2021-07-15
- Enrollment
- 805
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.